Treating GC in the Face of Dwindling Antibiotic Options – (2)
![](https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2015/06/GC-slider-copy.jpg?resize=640%2C180&ssl=1)
For GC antibiotics, the development path looks like a trip down the road less traveled, leading into some uncharted territory. Let’s take Melinta’s statement [1] at face value according to which the single 900 mg dose of delafloxacin failed because of Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (2)